Triple Trouble: A Case of Multiple Resistance Mechanisms after First Generation EGFR-TKI in NSCLC
Epidermal growth factor receptor (EGFR)-targeted therapy has become standard of care in advanced stages EGFR-mutant non-small cell lung cancer. Acquired resistance to first-line EGFR-tyrosine kinase inhibitor (TKI) and subsequent disease progression is a common problem and mostly due to a secondary...
Main Authors: | Mike Ralki, Brigitte Maes, Karin Pat, Jokke Wynants, Kristof Cuppens |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2019-08-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/502214 |
Similar Items
-
Treatment of Advanced NSCLC with Unknown EGFR Gene Status
__ TKI or Chemotherapy?
by: Xiaoqing LIU, et al.
Published: (2014-10-01) -
Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
by: Lihao Zhao, et al.
Published: (2019-12-01) -
Effect of EGFR-TKI on Lymphangiogenesis of Lung Cancer with EGFR Mutation
by: Minghui CAI, et al.
Published: (2014-12-01) -
Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
by: Wenxian Wang, et al.
Published: (2019-02-01) -
IL-22 Confers EGFR-TKI Resistance in NSCLC via the AKT and ERK Signaling Pathways
by: Xiaomeng Wang, et al.
Published: (2019-11-01)